Correlation of clinical progression in human immunodeficiency virus-infected children with in vitro zidovudine resistance measured by a direct quantitative peripheral blood lymphocyte assay

J Infect Dis. 1995 Aug;172(2):359-64. doi: 10.1093/infdis/172.2.359.

Abstract

A rapid method for determination of zidovudine resistance was developed and results were correlated with clinical outcome in human immunodeficiency virus (HIV)-infected children. The zidovudine susceptibilities of HIV-1 isolates from 34 children were determined through a direct quantitative peripheral blood lymphocyte assay and compared with results of the AIDS Clinical Trials Group resistance assay. Patients' peripheral blood lymphocytes were 5-fold diluted and cocultured with donor lymphocytes and varying concentrations of zidovudine. Isolates were defined as sensitive if inhibited by < or = 1.0 microM zidovudine and resistant at > 1.0 microM. Children (n = 21) with zidovudine-resistant virus had greater evidence of disease progression than did those with zidovudine-sensitive virus (n = 11) as demonstrated by failure to thrive (57% vs. 9%, P = .01) and opportunistic infections (48% vs. 0, P = .006). This assay may be useful as a screening tool for development of clinically relevant zidovudine resistance.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Child
  • Child, Preschool
  • Disease Progression
  • Drug Resistance, Microbial
  • Follow-Up Studies
  • HIV / drug effects
  • HIV Core Protein p24 / blood
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • Humans
  • Infant
  • Lymphocytes / drug effects
  • Microbial Sensitivity Tests / methods*
  • Zidovudine / pharmacology
  • Zidovudine / therapeutic use*

Substances

  • HIV Core Protein p24
  • Zidovudine